The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Associação Médica Brasileira (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000100033 |
Resumo: | SUMMARY OBJECTIVE To investigate the clinical efficacy and the possible mechanisms of saxagliptin in the treatment of type 2 diabetes mellitus (T2DM) combined with non-alcoholic fatty liver disease (NAFLD). METHODS A total of 95 T2DM and NAFLD patients were randomly divided into group A (saxagliptin group), group B (glimepiride group), and group C (glimepiride combined with polyene phosphatidylcholine group). RESULTS After intervention treatment for 24 w, body mass index (BMI), waist-to-hip ratio (WHR), glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), fasting insulin (FINS), homeostatic model assessment of insulin resistance (HOMA-IR), interleukin-6 (IL-6), triglyceride (TG), total cholesterol (TC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (γ-GT), and quantitative detection of liver steatosis of study subjects were observed, the action of liver steatosis in subjects of groups A and C were significantly different from those of group B; however, there were no differences between groups A and C. The FINS, HOMA-IR, and IL-6 of subjects in group A was lower than those in groups B and C; however, there were no significant differences between the latter two groups. CONCLUSION For T2DM combined with NAFLD patients, the saxagliptin treatment could not only effectively control blood glucose but also attenuate insulin resistance and inflammatory injury of the liver to improve fatty liver further. |
id |
AMB-1_85fdead84448c02e0fe43d8f93562961 |
---|---|
oai_identifier_str |
oai:scielo:S0104-42302019000100033 |
network_acronym_str |
AMB-1 |
network_name_str |
Revista da Associação Médica Brasileira (Online) |
repository_id_str |
|
spelling |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary dataDipeptidyl-peptidase IV inhibitors/therapeutic useDiabetes mellitus, type 2Interleukin-6Fatty liverNon-alcoholic fatty liver diseaseSUMMARY OBJECTIVE To investigate the clinical efficacy and the possible mechanisms of saxagliptin in the treatment of type 2 diabetes mellitus (T2DM) combined with non-alcoholic fatty liver disease (NAFLD). METHODS A total of 95 T2DM and NAFLD patients were randomly divided into group A (saxagliptin group), group B (glimepiride group), and group C (glimepiride combined with polyene phosphatidylcholine group). RESULTS After intervention treatment for 24 w, body mass index (BMI), waist-to-hip ratio (WHR), glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), fasting insulin (FINS), homeostatic model assessment of insulin resistance (HOMA-IR), interleukin-6 (IL-6), triglyceride (TG), total cholesterol (TC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (γ-GT), and quantitative detection of liver steatosis of study subjects were observed, the action of liver steatosis in subjects of groups A and C were significantly different from those of group B; however, there were no differences between groups A and C. The FINS, HOMA-IR, and IL-6 of subjects in group A was lower than those in groups B and C; however, there were no significant differences between the latter two groups. CONCLUSION For T2DM combined with NAFLD patients, the saxagliptin treatment could not only effectively control blood glucose but also attenuate insulin resistance and inflammatory injury of the liver to improve fatty liver further.Associação Médica Brasileira2019-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000100033Revista da Associação Médica Brasileira v.65 n.1 2019reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.65.1.33info:eu-repo/semantics/openAccessLi,Juan-JuanZhang,PingFan,BingGuo,Xiu-LiZheng,Zhe-Shueng2019-02-05T00:00:00Zoai:scielo:S0104-42302019000100033Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2019-02-05T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false |
dc.title.none.fl_str_mv |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data |
title |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data |
spellingShingle |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data Li,Juan-Juan Dipeptidyl-peptidase IV inhibitors/therapeutic use Diabetes mellitus, type 2 Interleukin-6 Fatty liver Non-alcoholic fatty liver disease |
title_short |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data |
title_full |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data |
title_fullStr |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data |
title_full_unstemmed |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data |
title_sort |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data |
author |
Li,Juan-Juan |
author_facet |
Li,Juan-Juan Zhang,Ping Fan,Bing Guo,Xiu-Li Zheng,Zhe-Shu |
author_role |
author |
author2 |
Zhang,Ping Fan,Bing Guo,Xiu-Li Zheng,Zhe-Shu |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Li,Juan-Juan Zhang,Ping Fan,Bing Guo,Xiu-Li Zheng,Zhe-Shu |
dc.subject.por.fl_str_mv |
Dipeptidyl-peptidase IV inhibitors/therapeutic use Diabetes mellitus, type 2 Interleukin-6 Fatty liver Non-alcoholic fatty liver disease |
topic |
Dipeptidyl-peptidase IV inhibitors/therapeutic use Diabetes mellitus, type 2 Interleukin-6 Fatty liver Non-alcoholic fatty liver disease |
description |
SUMMARY OBJECTIVE To investigate the clinical efficacy and the possible mechanisms of saxagliptin in the treatment of type 2 diabetes mellitus (T2DM) combined with non-alcoholic fatty liver disease (NAFLD). METHODS A total of 95 T2DM and NAFLD patients were randomly divided into group A (saxagliptin group), group B (glimepiride group), and group C (glimepiride combined with polyene phosphatidylcholine group). RESULTS After intervention treatment for 24 w, body mass index (BMI), waist-to-hip ratio (WHR), glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), fasting insulin (FINS), homeostatic model assessment of insulin resistance (HOMA-IR), interleukin-6 (IL-6), triglyceride (TG), total cholesterol (TC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (γ-GT), and quantitative detection of liver steatosis of study subjects were observed, the action of liver steatosis in subjects of groups A and C were significantly different from those of group B; however, there were no differences between groups A and C. The FINS, HOMA-IR, and IL-6 of subjects in group A was lower than those in groups B and C; however, there were no significant differences between the latter two groups. CONCLUSION For T2DM combined with NAFLD patients, the saxagliptin treatment could not only effectively control blood glucose but also attenuate insulin resistance and inflammatory injury of the liver to improve fatty liver further. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000100033 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000100033 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1806-9282.65.1.33 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Revista da Associação Médica Brasileira v.65 n.1 2019 reponame:Revista da Associação Médica Brasileira (Online) instname:Associação Médica Brasileira (AMB) instacron:AMB |
instname_str |
Associação Médica Brasileira (AMB) |
instacron_str |
AMB |
institution |
AMB |
reponame_str |
Revista da Associação Médica Brasileira (Online) |
collection |
Revista da Associação Médica Brasileira (Online) |
repository.name.fl_str_mv |
Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB) |
repository.mail.fl_str_mv |
||ramb@amb.org.br |
_version_ |
1754212833809137664 |